Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatm… Read more
Market Cap & Net Worth: Biodexa Pharmaceticals (BDRX)
Biodexa Pharmaceticals (NASDAQ:BDRX) has a market capitalization of $645.87K ($645.87K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #36531 globally and #11894 in its home market, demonstrating a -18.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biodexa Pharmaceticals's stock price $0.77 by its total outstanding shares 838787 (838.79K).
Biodexa Pharmaceticals Market Cap History: 2015 to 2026
Biodexa Pharmaceticals's market capitalization history from 2015 to 2026. Data shows change from $838.79 Billion to $645.87K (-74.56% CAGR).
Index Memberships
Biodexa Pharmaceticals is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #901 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2818 of 3165 |
Weight: Biodexa Pharmaceticals's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biodexa Pharmaceticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biodexa Pharmaceticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
147.50x
Biodexa Pharmaceticals's market cap is 147.50 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $838.79 Billion | $1.38 Million | -$10.10 Million | 610026.91x | N/A |
| 2016 | $838.79 Billion | $1.32 Million | -$6.16 Million | 634003.78x | N/A |
| 2017 | $838.79 Billion | $989.00K | -$11.71 Million | 848116.28x | N/A |
| 2018 | $260.02 Billion | $1.94 Million | -$10.37 Million | 134171.30x | N/A |
| 2019 | $115.64 Billion | $674.00K | -$10.09 Million | 171565.54x | N/A |
| 2020 | $62.74 Billion | $343.00K | -$22.19 Million | 182919.15x | N/A |
| 2021 | $35.23 Billion | $578.00K | -$5.46 Million | 60949.92x | N/A |
| 2022 | $6.61 Billion | $699.00K | -$7.66 Million | 9455.85x | N/A |
| 2023 | $56.20 Million | $381.00K | -$7.08 Million | 147.50x | N/A |
Competitor Companies of BDRX by Market Capitalization
Companies near Biodexa Pharmaceticals in the global market cap rankings as of March 19, 2026.
Key companies related to Biodexa Pharmaceticals by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Biodexa Pharmaceticals Historical Marketcap From 2015 to 2026
Between 2015 and today, Biodexa Pharmaceticals's market cap moved from $838.79 Billion to $ 645.87K, with a yearly change of -74.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $645.87K | -66.08% |
| 2025 | $1.90 Million | -43.95% |
| 2024 | $3.40 Million | -93.96% |
| 2023 | $56.20 Million | -99.15% |
| 2022 | $6.61 Billion | -81.24% |
| 2021 | $35.23 Billion | -43.85% |
| 2020 | $62.74 Billion | -45.74% |
| 2019 | $115.64 Billion | -55.53% |
| 2018 | $260.02 Billion | -69.00% |
| 2017 | $838.79 Billion | 0.00% |
| 2016 | $838.79 Billion | 0.00% |
| 2015 | $838.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Biodexa Pharmaceticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $645.87K USD |
| MoneyControl | $645.87K USD |
| MarketWatch | $645.87K USD |
| marketcap.company | $645.87K USD |
| Reuters | $645.87K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.